上海
*僅供醫學專業人士閱讀參考
埃萬妥單抗聯合方案在EGFR突變NSCLC伴腦轉移患者的一線與二線治療中均展現出卓越的顱內病灶控制能力和生存獲益，開啟了精準、全程管理的新時代。
*以下內容僅供醫療衛生專業人士瀏覽。
參考文獻：
[1]中國抗癌協會腫瘤病理專業委員會分子病理協作組, 中國醫師協會腫瘤多學科診療專業委員會. 非小細胞肺癌表皮生長因子受體20號外顯子插入突變檢測臨床實踐中國專家共識（2024版）[J]. 中華腫瘤雜志, 2024, 46(3):179-188.
[2]趙軍, 等. 中國驅動基因陽性非小細胞肺癌腦轉移臨床診療指南(2025版)[J].中國肺癌雜志, 2025(1).
[3]Shirish MG, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.
[4]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.
[5]Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[6]Chouaid C, et al. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 2025 May;203:108548.
[7]Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.
[8]Shih J, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.
[9]NCCN Guidelines Central Nervous System Cancers. Version 2.2025.
審批編碼：CP-552514
批準分發日期：11/17/2025
有效期：11/17/2026
*此文僅用于向醫療衛生專業人士提供科學信息，不代表平臺立場。
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
